Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Lancet Gastroenterol Hepatol

Retrieve available abstracts of 110 articles:
HTML format



Single Articles


    July 2021
  1. SASSON AN, Ingram RJM, Zhang Z, Taylor LM, et al
    The role of precision nutrition in the modulation of microbial composition and function in people with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021 Jul 13. pii: S2468-1253(21)00097.
    PubMed     Abstract available


  2. GARRIDO HMG, Grobusch MP, D'Haens GRAM, Goorhuis A, et al
    SARS-CoV-2 vaccination for patients with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021;6:523.
    PubMed    


  3. ALEXANDER JL, Kennedy NA, Lees CW, Ahmad T, et al
    SARS-CoV-2 vaccination for patients with inflammatory bowel disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2021;6:523-524.
    PubMed    


  4. DIN S, Gaya DR, Arnott IDR
    COVID-19: Colorectal cancer endoscopic surveillance in IBD.
    Lancet Gastroenterol Hepatol. 2021;6:526-527.
    PubMed    


    June 2021
  5. CROFT NM, Faubion WA Jr, Kugathasan S, Kierkus J, et al
    Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.
    Lancet Gastroenterol Hepatol. 2021 Jun 18. pii: S2468-1253(21)00142.
    PubMed     Abstract available


    May 2021
  6. ALEXANDER JL, Powell N
    SARS-CoV-2 vaccination in immunosuppressed patients with inflammatory bowel disease: should our approach change?
    Lancet Gastroenterol Hepatol. 2021 May 25. pii: S2468-1253(21)00184.
    PubMed    


  7. DANESE S, Parigi TL, Peyrin-Biroulet L, Ghosh S, et al
    Defining difficult-to-treat inflammatory bowel disease: why and how.
    Lancet Gastroenterol Hepatol. 2021 May 18. pii: S2468-1253(21)00141.
    PubMed    


  8. ALSOUD D, Verstockt B, Fiocchi C, Vermeire S, et al
    Breaking the therapeutic ceiling in drug development in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2021 May 18. pii: S2468-1253(21)00065.
    PubMed     Abstract available


  9. SEGAL JP, Kumar A, Raine T, Lamb CA, et al
    The impact of SARS-CoV-2 variants on IBD management.
    Lancet Gastroenterol Hepatol. 2021;6:343-344.
    PubMed    


    April 2021
  10. UNGAR B
    Infliximab discontinuation in patients with ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2021 Apr 19. pii: S2468-1253(21)00103.
    PubMed    


  11. KOBAYASHI T, Motoya S, Nakamura S, Yamamoto T, et al
    Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2021 Apr 19. pii: S2468-1253(21)00062.
    PubMed     Abstract available


  12. SHEN B, Kochhar GS, Navaneethan U, Cross RK, et al
    Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group.
    Lancet Gastroenterol Hepatol. 2021 Apr 16. pii: S2468-1253(20)30394.
    PubMed     Abstract available


    March 2021
  13. BARBERIO B, Zamani M, Black CJ, Savarino EV, et al
    Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    Lancet Gastroenterol Hepatol. 2021 Mar 12. pii: S2468-1253(21)00014.
    PubMed     Abstract available


  14. KEEFER L
    What can we do to tackle anxiety and depression in patients with inflammatory bowel disease?
    Lancet Gastroenterol Hepatol. 2021 Mar 12. pii: S2468-1253(21)00066.
    PubMed    


  15. SEGAL JP, Kayal M, Kochhar G, Dubinsky MC, et al
    The ileoanal pouch: the next frontier in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021;6:164-165.
    PubMed    


  16. JENA A, Jha DK, Sharma V
    Distinguishing intestinal tuberculosis from Crohn's disease.
    Lancet Gastroenterol Hepatol. 2021;6:159.
    PubMed    


  17. BANERJEE R, Pal P
    Distinguishing intestinal tuberculosis from Crohn's disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2021;6:159-160.
    PubMed    


    February 2021
  18. SEBASTIAN S, Walker GJ, Kennedy NA, Conley TE, et al
    Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study.
    Lancet Gastroenterol Hepatol. 2021 Feb 2. pii: S2468-1253(21)00016.
    PubMed     Abstract available


  19. SHEN B
    Acute severe ulcerative colitis: confronting an intensified stressor during the COVID-19 pandemic.
    Lancet Gastroenterol Hepatol. 2021 Feb 2. pii: S2468-1253(21)00009.
    PubMed    


  20. VERMA AM, Patel A, Subramanian S, Smith PJ, et al
    From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative.
    Lancet Gastroenterol Hepatol. 2021;6:88-89.
    PubMed    


    January 2021
  21. ALEXANDER JL, Moran GW, Gaya DR, Raine T, et al
    SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement.
    Lancet Gastroenterol Hepatol. 2021 Jan 25. pii: S2468-1253(21)00024.
    PubMed     Abstract available


    December 2020
  22. NG SC, Mak JWY, Pal P, Banerjee R, et al
    Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia.
    Lancet Gastroenterol Hepatol. 2020;5:1089-1100.
    PubMed     Abstract available


  23. BANERJEE R, Pal P, Mak JWY, Ng SC, et al
    Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia.
    Lancet Gastroenterol Hepatol. 2020;5:1076-1088.
    PubMed     Abstract available


  24. STRID H
    Prevalence of IBS-type symptoms in IBD.
    Lancet Gastroenterol Hepatol. 2020;5:1029-1031.
    PubMed    


    November 2020
  25. AZIZ I, Simren M
    The overlap between irritable bowel syndrome and organic gastrointestinal diseases.
    Lancet Gastroenterol Hepatol. 2020 Nov 12. pii: S2468-1253(20)30212.
    PubMed     Abstract available


    October 2020
  26. MA C, Panaccione R
    Harnessing localised delivery of gut-selective therapy for ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2020 Oct 5. pii: S2468-1253(20)30292.
    PubMed    


  27. ATREYA R, Peyrin-Biroulet L, Klymenko A, Augustyn M, et al
    Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial.
    Lancet Gastroenterol Hepatol. 2020 Oct 5. pii: S2468-1253(20)30301.
    PubMed     Abstract available


  28. AREBI N
    Surgery versus infliximab for Crohn's disease: should there be a change in clinical practice?
    Lancet Gastroenterol Hepatol. 2020;5:877-878.
    PubMed    


  29. BRENNER EJ, Ungaro RC, Colombel JF, Kappelman MD, et al
    IBD in the COVID-19 era: the value of international collaboration.
    Lancet Gastroenterol Hepatol. 2020;5:887-888.
    PubMed    


  30. STEVENS TW, Haasnoot ML, D'Haens GR, Buskens CJ, et al
    Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial.
    Lancet Gastroenterol Hepatol. 2020;5:900-907.
    PubMed     Abstract available


  31. FAIRBRASS KM, Costantino SJ, Gracie DJ, Ford AC, et al
    Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis.
    Lancet Gastroenterol Hepatol. 2020 Oct 1. pii: S2468-1253(20)30300.
    PubMed     Abstract available


    September 2020
  32. KUMAR A, Quraishi MN, Segal JP, Raine T, et al
    COVID-19 vaccinations in patients with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2020 Sep 21. pii: S2468-1253(20)30295.
    PubMed    


  33. RAINE T, Verstockt B, De Cruz P
    Immune therapies in ulcerative colitis: are we beyond anti-TNF yet?
    Lancet Gastroenterol Hepatol. 2020;5:794-796.
    PubMed    


  34. SLEUTJES JAM, de Vries AC, van der Woude CJ
    Ozanimod in Crohn's disease: a promising new player.
    Lancet Gastroenterol Hepatol. 2020;5:791-792.
    PubMed    


  35. FEAGAN BG, Sandborn WJ, Danese S, Wolf DC, et al
    Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study.
    Lancet Gastroenterol Hepatol. 2020;5:819-828.
    PubMed     Abstract available


    August 2020
  36. NGUYEN LH, Ortqvist AK, Cao Y, Simon TG, et al
    Antibiotic use and the development of inflammatory bowel disease: a national case-control study in Sweden.
    Lancet Gastroenterol Hepatol. 2020 Aug 17. pii: S2468-1253(20)30267.
    PubMed     Abstract available


  37. SOKOL H
    Antibiotics: a trigger for inflammatory bowel disease?
    Lancet Gastroenterol Hepatol. 2020 Aug 17. pii: S2468-1253(20)30208.
    PubMed    


  38. RUDDY J, Taft T, Siau K, Bollipo S, et al
    Emotional state should not be used to differentiate IBD from IBS.
    Lancet Gastroenterol Hepatol. 2020;5:723.
    PubMed    


  39. IACUCCI M, Cannatelli R, Labarile N, Ghosh S, et al
    Emotional state should not be used to differentiate IBD from IBS - Authors' reply.
    Lancet Gastroenterol Hepatol. 2020;5:723-724.
    PubMed    


    July 2020
  40. DING NS, An P, Dong W, Ding Y, et al
    Prevention of COVID-19 in patients with IBD - Authors' reply.
    Lancet Gastroenterol Hepatol. 2020;5:640-641.
    PubMed    


    June 2020
  41. ORR WC, Fass R, Sundaram SS, Scheimann AO, et al
    The effect of sleep on gastrointestinal functioning in common digestive diseases.
    Lancet Gastroenterol Hepatol. 2020;5:616-624.
    PubMed     Abstract available


    May 2020
  42. SEGAL JP, Quraishi MN, Bhala N, Brookes MJ, et al
    Prevention of COVID-19 in patients with IBD.
    Lancet Gastroenterol Hepatol. 2020 May 19. pii: S2468-1253(20)30153.
    PubMed    


  43. FIORINO G, Peyrin-Biroulet L, Danese S
    Protecting patients with IBD during the COVID-19 pandemic.
    Lancet Gastroenterol Hepatol. 2020 May 19. pii: S2468-1253(20)30152.
    PubMed    


  44. CHEN Y, Hu S, Wu H, Farraye FA, et al
    Patterns of care for inflammatory bowel disease in China during the COVID-19 pandemic.
    Lancet Gastroenterol Hepatol. 2020 May 13. pii: S2468-1253(20)30131.
    PubMed    


  45. D'AMICO F, Rahier JF, Leone S, Peyrin-Biroulet L, et al
    Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey.
    Lancet Gastroenterol Hepatol. 2020 May 13. pii: S2468-1253(20)30151.
    PubMed    


  46. HAN J, Zhu L, Wang Y, Zeng Z, et al
    Resumption of daily services in a gastroenterology department in Guangzhou, China, in the wake of COVID-19.
    Lancet Gastroenterol Hepatol. 2020 May 4. pii: S2468-1253(20)30133.
    PubMed    


  47. SELINGER CP
    Biologicals are the main contributor to cost of care for IBD: a European perspective.
    Lancet Gastroenterol Hepatol. 2020;5:421-422.
    PubMed    


  48. LOUGHMAN A, Staudacher HM
    Treating the individual with diet: is gut microbiome testing the answer?
    Lancet Gastroenterol Hepatol. 2020;5:437.
    PubMed    


    April 2020
  49. AN P, Ji M, Ren H, Su J, et al
    Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China.
    Lancet Gastroenterol Hepatol. 2020 Apr 17. pii: S2468-1253(20)30121.
    PubMed    


  50. IACUCCI M, Cannatelli R, Labarile N, Mao R, et al
    Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period.
    Lancet Gastroenterol Hepatol. 2020 Apr 16. pii: S2468-1253(20)30119.
    PubMed     Abstract available


  51. MUSHTAQ A, Kazi F
    Switching to biosimilars: boon or bust?
    Lancet Gastroenterol Hepatol. 2020;5:341-342.
    PubMed    


    March 2020
  52. ZINGONE F, Savarino EV
    Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak.
    Lancet Gastroenterol Hepatol. 2020 Mar 25. pii: S2468-1253(20)30085.
    PubMed    


  53. SHIVAJI UN, Nardone OM, Cannatelli R, Smith SC, et al
    Small molecule oral targeted therapies in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2020 Mar 11. pii: S2468-1253(19)30414.
    PubMed     Abstract available


  54. MAO R, Liang J, Shen J, Ghosh S, et al
    Implications of COVID-19 for patients with pre-existing digestive diseases.
    Lancet Gastroenterol Hepatol. 2020 Mar 11. pii: S2468-1253(20)30076.
    PubMed    


  55. OLESEN SW, Panchal P, Chen J, Budree S, et al
    Global disparities in faecal microbiota transplantation research.
    Lancet Gastroenterol Hepatol. 2020;5:241.
    PubMed    


    February 2020
  56. BURISCH J, Vardi H, Schwartz D, Friger M, et al
    Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study.
    Lancet Gastroenterol Hepatol. 2020 Feb 13. pii: S2468-1253(20)30012.
    PubMed     Abstract available


  57. HOU JK
    Colorectal cancer in Crohn's disease: closing the gap.
    Lancet Gastroenterol Hepatol. 2020 Feb 13. pii: S2468-1253(20)30046.
    PubMed    


  58. OLEN O, Erichsen R, Sachs MC, Pedersen L, et al
    Colorectal cancer in Crohn's disease: a Scandinavian population-based cohort study.
    Lancet Gastroenterol Hepatol. 2020 Feb 13. pii: S2468-1253(20)30005.
    PubMed     Abstract available


  59. HASTINGS B
    Successful control of ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2020;5:116.
    PubMed    


    January 2020
  60. SHEN B, Kochhar G, Navaneethan U, Farraye FA, et al
    Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group.
    Lancet Gastroenterol Hepatol. 2020 Jan 16. pii: S2468-1253(19)30366.
    PubMed     Abstract available


  61. CHAPMAN TP, Gomes CF, Louis E, Colombel JF, et al
    De-escalation of immunomodulator and biological therapy in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2020;5:63-79.
    PubMed     Abstract available


  62. NOOR NM, Verstockt B, Parkes M, Lee JC, et al
    Personalised medicine in Crohn's disease.
    Lancet Gastroenterol Hepatol. 2020;5:80-92.
    PubMed     Abstract available


    December 2019
  63. WALJEE AK, Higgins PDR, Jensen CB, Villumsen M, et al
    Anti-tumour necrosis factor-alpha therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study.
    Lancet Gastroenterol Hepatol. 2019 Dec 10. pii: S2468-1253(19)30362.
    PubMed     Abstract available


  64. IACUCCI M, Cannatelli R, Tontini GE, Panaccione R, et al
    Improving the quality of surveillance colonoscopy in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2019;4:971-983.
    PubMed     Abstract available


  65. O'KEEFE SJ
    The association between dietary fibre deficiency and high-income lifestyle-associated diseases: Burkitt's hypothesis revisited.
    Lancet Gastroenterol Hepatol. 2019;4:984-996.
    PubMed     Abstract available


    November 2019
  66. D'HAENS G, Pinzani M
    Intestinal and hepatic fibrosis: how are they similar?
    Lancet Gastroenterol Hepatol. 2019;4:820-822.
    PubMed    


    October 2019
  67. JAIRATH V, Feagan BG
    Global burden of inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2019 Oct 21. pii: S2468-1253(19)30358.
    PubMed    



  68. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
    Lancet Gastroenterol Hepatol. 2019 Oct 21. pii: S2468-1253(19)30333.
    PubMed     Abstract available


    September 2019
  69. WINTZELL V, Svanstrom H, Melbye M, Jess T, et al
    Use of tumour necrosis factor-alpha inhibitors and the risk of serious infection in paediatric inflammatory bowel disease in Denmark: a nationwide cohort study.
    Lancet Gastroenterol Hepatol. 2019 Sep 4. pii: S2468-1253(19)30266.
    PubMed     Abstract available


  70. RUEMMELE FM
    Safety of anti-TNF biologics in paediatric inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2019 Sep 4. pii: S2468-1253(19)30292.
    PubMed    


  71. FURLOW B
    The challenge of inflammatory bowel disease in India.
    Lancet Gastroenterol Hepatol. 2019;4:670-671.
    PubMed    


    July 2019
  72. MUSHTAQ A
    Supporting travel in patients with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2019;4:499-500.
    PubMed    


    June 2019
  73. ARGOLLO M, Gilardi D, Peyrin-Biroulet C, Chabot JF, et al
    Comorbidities in inflammatory bowel disease: a call for action.
    Lancet Gastroenterol Hepatol. 2019 Jun 3. pii: S2468-1253(19)30173.
    PubMed     Abstract available


  74. MOTTA I, Perricone G
    Ulcerative pyoderma gangrenosum in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2019;4:488.
    PubMed    


    May 2019
  75. GRACIE DJ, Hamlin PJ, Ford AC
    The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment.
    Lancet Gastroenterol Hepatol. 2019 May 20. pii: S2468-1253(19)30089.
    PubMed     Abstract available


    February 2019
  76. KING JA, Underwood FE, Panaccione N, Quan J, et al
    Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries: a population-based study of countries in the Organisation for Economic Co-operation and Development.
    Lancet Gastroenterol Hepatol. 2019 Feb 11. pii: S2468-1253(19)30013.
    PubMed     Abstract available


  77. TAYLOR SA, Halligan S, Bhatnagar G, Gupta A, et al
    Diagnostic accuracy of MRE and ultrasound for Crohn's disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2019;4:96.
    PubMed    


  78. NOVAK K, Maaser C, Wilkens R, Maconi G, et al
    Diagnostic accuracy of MRE and ultrasound for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2019;4:95-96.
    PubMed    


    November 2018
  79. ATREYA R, Neurath MF
    Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2018;3:790-802.
    PubMed     Abstract available


  80. CARBONNEL F
    Networks meet ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2018;3:730-731.
    PubMed    


    October 2018
  81. JAIRATH V, Jeyarajah J, Zou G, Parker CE, et al
    A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score.
    Lancet Gastroenterol Hepatol. 2018 Oct 17. pii: S2468-1253(18)30306.
    PubMed     Abstract available


  82. CARBONNEL F
    Towards more efficient assessment of ulcerative colitis drugs.
    Lancet Gastroenterol Hepatol. 2018 Oct 17. pii: S2468-1253(18)30342.
    PubMed    


  83. GECSE KB
    Risankizumab: a game changer in Crohn's disease?
    Lancet Gastroenterol Hepatol. 2018;3:656-657.
    PubMed    


  84. FEAGAN BG, Panes J, Ferrante M, Kaser A, et al
    Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
    Lancet Gastroenterol Hepatol. 2018;3:671-680.
    PubMed     Abstract available


    September 2018
  85. GECSE KB, Vermeire S
    Differential diagnosis of inflammatory bowel disease: imitations and complications.
    Lancet Gastroenterol Hepatol. 2018;3:644-653.
    PubMed     Abstract available


    August 2018
  86. NGUYEN NH, Fumery M, Dulai PS, Prokop LJ, et al
    Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses.
    Lancet Gastroenterol Hepatol. 2018 Aug 16. pii: S2468-1253(18)30231.
    PubMed     Abstract available


    June 2018
  87. DE KOCK I, Delrue L, Hindryckx P
    An optimal METRIC for imaging in small bowel Crohn's disease.
    Lancet Gastroenterol Hepatol. 2018 Jun 15. pii: S2468-1253(18)30197.
    PubMed    


  88. TAYLOR SA, Mallett S, Bhatnagar G, Baldwin-Cleland R, et al
    Diagnostic accuracy of magnetic resonance enterography and small bowel ultrasound for the extent and activity of newly diagnosed and relapsed Crohn's disease (METRIC): a multicentre trial.
    Lancet Gastroenterol Hepatol. 2018 Jun 15. pii: S2468-1253(18)30161.
    PubMed     Abstract available


  89. POUILLON L, Laurent V, Pouillon M, Bossuyt P, et al
    Diffusion-weighted MRI in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2018;3:433-443.
    PubMed     Abstract available


    April 2018
  90. THE LANCET GASTROENTEROLOGY HE
    Illuminating the invisible.
    Lancet Gastroenterol Hepatol. 2018;3:213.
    PubMed    


    March 2018
  91. BONOVAS S, Peyrin-Biroulet L, Danese S
    Infliximab biosimilar CT-P13 for inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2018 Mar 29. pii: S2468-1253(18)30116.
    PubMed    


  92. STRIK AS, van de Vrie W, Bloemsaat-Minekus JPJ, Nurmohamed M, et al
    Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
    Lancet Gastroenterol Hepatol. 2018 Mar 29. pii: S2468-1253(18)30082.
    PubMed     Abstract available


  93. VLEUGELS JLA, Rutter MD, Ragunath K, Rees CJ, et al
    Chromoendoscopy versus autofluorescence imaging for neoplasia detection in patients with longstanding ulcerative colitis (FIND-UC): an international, multicentre, randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2018 Mar 19. pii: S2468-1253(18)30055.
    PubMed     Abstract available


  94. PICCO MF
    Is autofluorescence inferior to chromoendoscopy for dysplasia detection in ulcerative colitis?
    Lancet Gastroenterol Hepatol. 2018 Mar 19. pii: S2468-1253(18)30091.
    PubMed    


    September 2017
  95. ASHTON JJ, Beattie RM
    Improving remission rates in newly diagnosed paediatric ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2017 Sep 19. pii: S2468-1253(17)30289.
    PubMed    


  96. HYAMS JS, Davis S, Mack DR, Boyle B, et al
    Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study.
    Lancet Gastroenterol Hepatol. 2017 Sep 19. pii: S2468-1253(17)30252.
    PubMed     Abstract available


  97. WHITE LS, Kaye S
    Concomitant arterial and venous thromboembolism in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2017;2:690.
    PubMed    


  98. KOLIANI-PACE JL, Siegel CA
    Beyond disease activity to overall disease severity in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2017;2:624-626.
    PubMed    


    July 2017
  99. ROGLER G
    Resolution of inflammation in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2017;2:521-530.
    PubMed     Abstract available


    May 2017
  100. SIEGMUND B
    Cytomegalovirus infection associated with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2017;2:369-376.
    PubMed     Abstract available


    April 2017
  101. BOPANNA S, Ananthakrishnan AN, Kedia S, Yajnik V, et al
    Risk of colorectal cancer in Asian patients with ulcerative colitis: a systematic review and meta-analysis.
    Lancet Gastroenterol Hepatol. 2017;2:269-276.
    PubMed     Abstract available


  102. KAPLAN GG
    Colon cancer in Asian patients with ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2017;2:238-239.
    PubMed    


    March 2017
  103. MIRKOV MU, Verstockt B, Cleynen I
    Genetics of inflammatory bowel disease: beyond NOD2.
    Lancet Gastroenterol Hepatol. 2017;2:224-234.
    PubMed     Abstract available


  104. GRACIE DJ, Irvine AJ, Sood R, Mikocka-Walus A, et al
    Effect of psychological therapy on disease activity, psychological comorbidity, and quality of life in inflammatory bowel disease: a systematic review and meta-analysis.
    Lancet Gastroenterol Hepatol. 2017;2:189-199.
    PubMed     Abstract available


  105. WALKER JR
    Understanding and management of anxiety and mood disorders in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2017;2:148-150.
    PubMed    


    December 2016
  106. KAPLAN GG, Ng SC
    Globalisation of inflammatory bowel disease: perspectives from the evolution of inflammatory bowel disease in the UK and China.
    Lancet Gastroenterol Hepatol. 2016;1:307-316.
    PubMed     Abstract available


    October 2016
  107. MOHAMMADI D
    The curious case of inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2016;1:94.
    PubMed    


    September 2016
  108. WILLIAMS JG, Alam MF, Alrubaiy L, Arnott I, et al
    Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial.
    Lancet Gastroenterol Hepatol. 2016;1:15-24.
    PubMed     Abstract available


  109. ANANTHAKRISHNAN AN
    Infliximab or ciclosporin for acute severe ulcerative colitis?
    Lancet Gastroenterol Hepatol. 2016;1:2-3.
    PubMed    


  110. HORSLEY-SILVA JL, Carey EJ, Lindor KD
    Advances in primary sclerosing cholangitis.
    Lancet Gastroenterol Hepatol. 2016;1:68-77.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: